Alkem Labs shares fell by 2% after the US Food and Drug Administration (FDA) issued a warning letter to its manufacturing facility in Daman. Despite this, the company confirmed that it continues to manufacture and supply approved products to the US market, with no significant impact on its current operations or financial status.
- US FDA issued a warning letter following an inspection of Alkem Labs' Daman facility.
- The inspection took place from April 20 to May 1, 2026, and resulted in an Official Action Indicated (OAI) status.
- Alkem Labs continues production and supply of approved products without material operational or financial impact.
- The company's promoter-group sold shares worth ₹301.9 crore in a block deal.
- Consolidated net profit fell 14.4% year-on-year in Q2 FY27, while revenue rose 13.8%.
What led to the US FDA warning letter for Alkem Labs?
The US FDA conducted an inspection of Alkem Labs' manufacturing facility located in Amaliya, Daman, between April 20 and May 1, 2026. During this inspection, the FDA classified the facility's status as Official Action Indicated (OAI), which means significant violations were observed. Consequently, the FDA issued a warning letter to the company regarding these findings.
How is Alkem Labs responding to the FDA warning?
Alkem Labs stated that despite the warning letter, it continues to manufacture and supply approved pharmaceutical products from the Daman facility to the US market. The company emphasized that there is no material impact on its current operations, financial status, or other activities. This indicates that the company is managing the situation without disruption to its business.
What recent financial changes has Alkem Labs experienced?
In the second quarter of the 2026-27 financial year (Q2 FY27), Alkem Labs reported a consolidated net profit of ₹667.1 crore, which is a 14.4% decrease compared to ₹779.11 crore in the same quarter the previous year. However, the company's consolidated revenue from operations increased by 13.8% year-on-year to ₹4,552 crore, up from ₹4,001 crore in Q2 FY26.
What recent stock market activity has involved Alkem Labs?
On November 17, 2026, the promoter-group family trust of Alkem Labs, Samprada & Nanhamati Singh Family Trust, sold 5.98 crore shares in a block deal worth ₹301.9 crore. Major mutual funds, including DSP Mutual Fund, Nippon India Mutual Fund, ICICI Prudential Mutual Fund, and HDFC Mutual Fund, purchased these shares at ₹5,050 each. Following the FDA warning letter, Alkem Labs' shares traded 1.48% lower at ₹5,145 per equity share on November 19.
What is the current market status of Alkem Labs?
As of November 19, 2026, Alkem Laboratories has a market capitalization of ₹61,402.61 crore according to NSE data. The stock has experienced a 3% gain over the past month but has fallen 3% in the past week and 6% year-to-date. The 52-week high was ₹5,933.50 per share on January 13, 2026, and the 52-week low was ₹4,811 on October 22, 2026.

